Aardvark Therapeutics

AARD

Market cap $144M

SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.

SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome (“PWS”) asset.

SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.

SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome (“PWS”). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.